Prime shows how carve-in wins for clients—it’s better than carve-out.

June 1, 2020

For the first time, Prime’s puts its carve-in analytics through a rigorous scientific peer review. It’s clear.  This published, peer reviewed study showed  Regence and Prime carve-in pharmacy was associated with lowered overall health care costs.

Carve-out is out. This study used medical data and followed members for two years. The final cohorts consisted of 205,835 carve-in and 125,555 carve-out members.

Compared to the carve out members, members with carve-in benefits had an average:

  • $148 lower total medical cost PMPY 
  • 15% lower odds of hospitalization 
  • 7% lower odds of ED visit

In 5 of 7 chronic conditions, members with carve-in benefits had significant lower costs and medical event odds as shown here: 

  • 12%-17% lower medical costs
  • 22%-36% lower odds of hospitalization 
  • 16%-20% lower odds of ED visit 

The study findings indicate that integrated, carve-in pharmacy and medical benefits are associated with lower medical costs, fewer hospitalizations, and fewer ED visits.

This study, co-authored by researchers at Prime and Regence Health Plans, is to our knowledge, the only scientifically peer-reviewed study published on the subject. The authors received a platinum award for this research, which is published in the peer-reviewed Journal of Managed Care & Specialty Pharmacy (JMCP).

Medical Costs and Health Care Utilization Among Self-Insured Members with Carve-In Versus Carve-Out Pharmacy Benefits (Spring 2020)

Related news

Perspectives

March 30, 2023

Drug oversupply, or stockpiling, due to overlapping drug refills can cause unnecessary drug costs

If you have a chronic condition, your pharmacy may notify you advance of…

Perspectives

March 28, 2023

Biosimilars are at the door, Part 3

News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…

Perspectives

March 27, 2023

Specialty Drug Pipeline Update: March 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…